DE69711024T2 - Steuerung des heilungsprozesses - Google Patents
Steuerung des heilungsprozessesInfo
- Publication number
- DE69711024T2 DE69711024T2 DE69711024T DE69711024T DE69711024T2 DE 69711024 T2 DE69711024 T2 DE 69711024T2 DE 69711024 T DE69711024 T DE 69711024T DE 69711024 T DE69711024 T DE 69711024T DE 69711024 T2 DE69711024 T2 DE 69711024T2
- Authority
- DE
- Germany
- Prior art keywords
- thrombin inhibitor
- molecular weight
- low molecular
- peptide
- polysaccharide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000035876 healing Effects 0.000 title description 2
- 229940122388 Thrombin inhibitor Drugs 0.000 claims abstract description 56
- 239000003868 thrombin inhibitor Substances 0.000 claims abstract description 56
- 101000712605 Theromyzon tessulatum Theromin Proteins 0.000 claims abstract description 39
- 102000009123 Fibrin Human genes 0.000 claims abstract description 29
- 108010073385 Fibrin Proteins 0.000 claims abstract description 29
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims abstract description 29
- 229950003499 fibrin Drugs 0.000 claims abstract description 29
- 150000004676 glycans Chemical class 0.000 claims abstract description 28
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 28
- 239000005017 polysaccharide Substances 0.000 claims abstract description 28
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 23
- 231100000241 scar Toxicity 0.000 claims abstract description 22
- 229920001661 Chitosan Polymers 0.000 claims abstract description 19
- 238000000034 method Methods 0.000 claims abstract description 12
- 230000008569 process Effects 0.000 claims abstract description 9
- 230000029663 wound healing Effects 0.000 claims abstract description 9
- 238000004519 manufacturing process Methods 0.000 claims abstract description 7
- 239000012528 membrane Substances 0.000 claims description 20
- 230000015572 biosynthetic process Effects 0.000 claims description 19
- WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 claims description 17
- 229960002137 melagatran Drugs 0.000 claims description 16
- DKWNMCUOEDMMIN-PKOBYXMFSA-N melagatran Chemical compound C1=CC(C(=N)N)=CC=C1CNC(=O)[C@H]1N(C(=O)[C@H](NCC(O)=O)C2CCCCC2)CC1 DKWNMCUOEDMMIN-PKOBYXMFSA-N 0.000 claims description 16
- CDPROXZBMHOBTQ-SJORKVTESA-N 2-[[(2r)-3-cyclohexyl-1-[(2s)-2-[3-(diaminomethylideneamino)propylcarbamoyl]piperidin-1-yl]-1-oxopropan-2-yl]amino]acetic acid Chemical group NC(N)=NCCCNC(=O)[C@@H]1CCCCN1C(=O)[C@H](NCC(O)=O)CC1CCCCC1 CDPROXZBMHOBTQ-SJORKVTESA-N 0.000 claims description 10
- 239000003527 fibrinolytic agent Substances 0.000 claims description 10
- 229950003291 inogatran Drugs 0.000 claims description 10
- 102000007625 Hirudins Human genes 0.000 claims description 9
- 108010007267 Hirudins Proteins 0.000 claims description 9
- 229940006607 hirudin Drugs 0.000 claims description 9
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 108010023197 Streptokinase Proteins 0.000 claims description 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 4
- 229960005202 streptokinase Drugs 0.000 claims description 4
- 230000002776 aggregation Effects 0.000 claims description 3
- 238000004220 aggregation Methods 0.000 claims description 3
- 229940127557 pharmaceutical product Drugs 0.000 claims description 3
- 108010001014 Plasminogen Activators Proteins 0.000 claims description 2
- 102000001938 Plasminogen Activators Human genes 0.000 claims description 2
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims description 2
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims description 2
- 229940127126 plasminogen activator Drugs 0.000 claims description 2
- 229960005356 urokinase Drugs 0.000 claims description 2
- 230000001419 dependent effect Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 1
- 230000010118 platelet activation Effects 0.000 claims 1
- 230000009772 tissue formation Effects 0.000 abstract description 5
- 230000005764 inhibitory process Effects 0.000 abstract description 4
- 230000002265 prevention Effects 0.000 abstract description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 39
- 210000002784 stomach Anatomy 0.000 description 22
- 210000001519 tissue Anatomy 0.000 description 21
- 206010063560 Excessive granulation tissue Diseases 0.000 description 20
- 210000001126 granulation tissue Anatomy 0.000 description 20
- 208000014674 injury Diseases 0.000 description 17
- 210000004379 membrane Anatomy 0.000 description 17
- 239000000243 solution Substances 0.000 description 17
- 241000700159 Rattus Species 0.000 description 15
- 210000000936 intestine Anatomy 0.000 description 14
- 210000004185 liver Anatomy 0.000 description 14
- 210000002747 omentum Anatomy 0.000 description 13
- 239000007975 buffered saline Substances 0.000 description 12
- 230000004054 inflammatory process Effects 0.000 description 12
- 238000005086 pumping Methods 0.000 description 12
- 230000008733 trauma Effects 0.000 description 12
- 206010061218 Inflammation Diseases 0.000 description 11
- 210000003205 muscle Anatomy 0.000 description 11
- 230000003204 osmotic effect Effects 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 10
- 239000000499 gel Substances 0.000 description 10
- 210000003200 peritoneal cavity Anatomy 0.000 description 10
- 208000027418 Wounds and injury Diseases 0.000 description 9
- 238000005406 washing Methods 0.000 description 9
- 230000001717 pathogenic effect Effects 0.000 description 8
- 238000001356 surgical procedure Methods 0.000 description 8
- 210000000056 organ Anatomy 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 210000003195 fascia Anatomy 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 206010052428 Wound Diseases 0.000 description 4
- 210000000683 abdominal cavity Anatomy 0.000 description 4
- 210000001772 blood platelet Anatomy 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 230000036470 plasma concentration Effects 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 229920002674 hyaluronan Polymers 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 2
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 description 2
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229960004676 antithrombotic agent Drugs 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000011260 co-administration Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000010408 film Substances 0.000 description 2
- 229920000669 heparin Polymers 0.000 description 2
- 229960002897 heparin Drugs 0.000 description 2
- KIUKXJAPPMFGSW-MNSSHETKSA-N hyaluronan Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)C1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H](C(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-MNSSHETKSA-N 0.000 description 2
- 229940099552 hyaluronan Drugs 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 230000007480 spreading Effects 0.000 description 2
- 238000003892 spreading Methods 0.000 description 2
- 238000011477 surgical intervention Methods 0.000 description 2
- 210000002435 tendon Anatomy 0.000 description 2
- 210000000689 upper leg Anatomy 0.000 description 2
- 208000012260 Accidental injury Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 229920001287 Chondroitin sulfate Polymers 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920000045 Dermatan sulfate Polymers 0.000 description 1
- 206010017076 Fracture Diseases 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 229920000288 Keratan sulfate Polymers 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 208000031737 Tissue Adhesions Diseases 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 230000001851 biosynthetic effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000003518 caustics Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940107200 chondroitin sulfates Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- 238000005470 impregnation Methods 0.000 description 1
- 208000000509 infertility Diseases 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 231100000535 infertility Toxicity 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 208000003243 intestinal obstruction Diseases 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 238000002357 laparoscopic surgery Methods 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 230000000771 oncological effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 238000012829 orthopaedic surgery Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 210000004116 schwann cell Anatomy 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008718 systemic inflammatory response Effects 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 229960000187 tissue plasminogen activator Drugs 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/04—Macromolecular materials
- A61L31/043—Proteins; Polypeptides; Degradation products thereof
- A61L31/047—Other specific proteins or polypeptides not covered by A61L31/044 - A61L31/046
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/164—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- A61K38/166—Streptokinase
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/49—Urokinase; Tissue plasminogen activator
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/57—Protease inhibitors from animals; from humans
- A61K38/58—Protease inhibitors from animals; from humans from leeches, e.g. hirudin, eglin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Surgery (AREA)
- Vascular Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Tropical Medicine & Parasitology (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Control Of Temperature (AREA)
- Diaphragms For Electromechanical Transducers (AREA)
- General Induction Heating (AREA)
- Control Of Steam Boilers And Waste-Gas Boilers (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Moulding By Coating Moulds (AREA)
- Controlling Rewinding, Feeding, Winding, Or Abnormalities Of Webs (AREA)
- Control Of Metal Rolling (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE9600216A SE9600216D0 (sv) | 1996-01-18 | 1996-01-18 | Styrning av läkningsprocesser |
| PCT/SE1997/000057 WO1997025994A1 (en) | 1996-01-18 | 1997-01-16 | Control of healing process |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE69711024D1 DE69711024D1 (de) | 2002-04-18 |
| DE69711024T2 true DE69711024T2 (de) | 2002-09-19 |
Family
ID=20401098
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE69711024T Expired - Lifetime DE69711024T2 (de) | 1996-01-18 | 1997-01-16 | Steuerung des heilungsprozesses |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US6174855B1 (2) |
| EP (1) | EP0874634B1 (2) |
| JP (2) | JP4112006B2 (2) |
| KR (1) | KR19990077331A (2) |
| CN (1) | CN1213309A (2) |
| AT (1) | ATE214280T1 (2) |
| AU (1) | AU701260B2 (2) |
| BR (1) | BR9707005A (2) |
| CA (1) | CA2241983A1 (2) |
| CZ (1) | CZ225098A3 (2) |
| DE (1) | DE69711024T2 (2) |
| HU (1) | HUP9902029A3 (2) |
| IL (1) | IL125375A0 (2) |
| IS (1) | IS4782A (2) |
| NO (1) | NO983295D0 (2) |
| NZ (1) | NZ326003A (2) |
| PL (1) | PL327828A1 (2) |
| SE (1) | SE9600216D0 (2) |
| TR (1) | TR199801365T2 (2) |
| WO (1) | WO1997025994A1 (2) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE9900043D0 (sv) * | 1999-01-11 | 1999-01-11 | Astra Ab | New use |
| SE9900070D0 (sv) * | 1999-01-13 | 1999-01-13 | Astra Ab | New use |
| JP4351041B2 (ja) * | 2001-06-13 | 2009-10-28 | ザ・ユニバーシティ・オブ・シドニー | 傷治癒のための処置および組成物 |
| US7202066B2 (en) * | 2002-01-29 | 2007-04-10 | Carrington Laboratories, Inc. | Combination of a growth factor and a protease enzyme |
| CN1929849A (zh) * | 2003-10-21 | 2007-03-14 | 株式会社奈特克 | 包括含糖链的脱乙酰壳多糖衍生物的内窥镜手术用粘膜膨胀液组合物 |
| US7795205B2 (en) * | 2004-04-12 | 2010-09-14 | Canyon Pharmaceuticals, Inc. | Methods for effecting regression of tumor mass and size in a metastasized pancreatic tumor |
| US8414907B2 (en) | 2005-04-28 | 2013-04-09 | Warsaw Orthopedic, Inc. | Coatings on medical implants to guide soft tissue healing |
| US9119901B2 (en) | 2005-04-28 | 2015-09-01 | Warsaw Orthopedic, Inc. | Surface treatments for promoting selective tissue attachment to medical impants |
| US7450296B2 (en) | 2006-01-30 | 2008-11-11 | Taiwan Semiconductor Manufacturing Company, Ltd. | Method and system for patterning alignment marks on a transparent substrate |
| EP2023874A4 (en) * | 2006-06-02 | 2009-07-08 | Bioseek Inc | METHOD FOR IDENTIFYING ACTIVE SUBSTANCES AND THEIR USE FOR THE PREVENTION OF RESTENOSIS |
| EP2707485B1 (en) | 2011-05-09 | 2016-12-14 | The University Court of The University Of Glasgow | Methods of modulating micrornas in the treatment of pulmonary arterial hypertension |
| DE102014112212A1 (de) | 2014-08-26 | 2016-03-03 | Akesion Gmbh | Rekombinante Fusionsproteine zur Vorbeugung oder Behandlung von Adhäsionen bei Geweben oder Organen |
| EP3535390A4 (en) * | 2016-11-02 | 2020-11-25 | Inc. Aronora | COMBINATION OF THROMBIN E-WE ANALOGUE AND FIBRINOLYTIC |
| CN106729676A (zh) * | 2016-12-07 | 2017-05-31 | 杭州市萧山区中医院 | 水蛭素用于制备治疗术后肌腱粘连的药物中的应用 |
| JP7264589B2 (ja) * | 2017-12-25 | 2023-04-25 | 株式会社 資生堂 | トロンビンの抑制作用を指標とした皮膚状態改善剤のスクリーニング方法、及びトロンビン作用阻害剤を含む皮膚状態改善剤 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4326532A (en) * | 1980-10-06 | 1982-04-27 | Minnesota Mining And Manufacturing Company | Antithrombogenic articles |
| US4532134A (en) * | 1981-04-06 | 1985-07-30 | Malette William Graham | Method of achieving hemostasis, inhibiting fibroplasia, and promoting tissue regeneration in a tissue wound |
| JPS61253065A (ja) | 1985-05-02 | 1986-11-10 | 片倉チツカリン株式会社 | キトサン誘導体およびコラ−ゲンの複合材の医用材料およびその製造法 |
| US5112608A (en) * | 1987-03-13 | 1992-05-12 | Incyte Pharmaceuticals | Use of protease nexin-I to mediate wound healing |
| NL8902406A (nl) * | 1989-09-27 | 1991-04-16 | Hendrik Coenraad Hemker Prof D | Werkwijze voor het bepalen van de endogene trombinepotentiaal van plasma, en bloed alsmede een bij deze werkwijze te gebruiken kit. |
| DK0426368T3 (da) * | 1989-10-31 | 1995-03-13 | Howmedica | Præparater indeholdende chitinderivater til forebyggelse af adhæsion |
| US5209776A (en) | 1990-07-27 | 1993-05-11 | The Trustees Of Columbia University In The City Of New York | Tissue bonding and sealing composition and method of using the same |
| JPH04112006A (ja) * | 1990-08-31 | 1992-04-14 | Seiji Ichikawa | セメント液作成方法 |
| US5792835A (en) * | 1991-09-05 | 1998-08-11 | Baxter International Inc. | Method of preparing a topical fibrinogen complex |
| SE9103612D0 (sv) * | 1991-12-04 | 1991-12-04 | Astra Ab | New peptide derivatives |
| DE4200080A1 (de) * | 1992-01-03 | 1993-09-30 | Reinmueller Johannes | Pharmazeutische Zusammensetzung zur Wund-, Narben- und Keloidbehandlung |
| SE9301916D0 (sv) * | 1993-06-03 | 1993-06-03 | Ab Astra | New peptides derivatives |
-
1996
- 1996-01-18 SE SE9600216A patent/SE9600216D0/xx unknown
-
1997
- 1997-01-16 AT AT97900852T patent/ATE214280T1/de not_active IP Right Cessation
- 1997-01-16 WO PCT/SE1997/000057 patent/WO1997025994A1/en not_active Ceased
- 1997-01-16 TR TR1998/01365T patent/TR199801365T2/xx unknown
- 1997-01-16 PL PL97327828A patent/PL327828A1/xx unknown
- 1997-01-16 HU HU9902029A patent/HUP9902029A3/hu unknown
- 1997-01-16 NZ NZ326003A patent/NZ326003A/en unknown
- 1997-01-16 JP JP52591797A patent/JP4112006B2/ja not_active Expired - Fee Related
- 1997-01-16 DE DE69711024T patent/DE69711024T2/de not_active Expired - Lifetime
- 1997-01-16 IL IL12537597A patent/IL125375A0/xx unknown
- 1997-01-16 BR BR9707005A patent/BR9707005A/pt not_active Application Discontinuation
- 1997-01-16 CA CA002241983A patent/CA2241983A1/en not_active Abandoned
- 1997-01-16 KR KR1019980705478A patent/KR19990077331A/ko not_active Withdrawn
- 1997-01-16 EP EP97900852A patent/EP0874634B1/en not_active Expired - Lifetime
- 1997-01-16 CN CN97193027A patent/CN1213309A/zh active Pending
- 1997-01-16 AU AU13271/97A patent/AU701260B2/en not_active Ceased
- 1997-01-16 US US09/101,351 patent/US6174855B1/en not_active Expired - Fee Related
- 1997-01-16 CZ CZ982250A patent/CZ225098A3/cs unknown
-
1998
- 1998-06-24 IS IS4782A patent/IS4782A/is unknown
- 1998-07-16 NO NO983295A patent/NO983295D0/no not_active Application Discontinuation
-
2008
- 2008-02-14 JP JP2008033125A patent/JP2008163036A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP4112006B2 (ja) | 2008-07-02 |
| WO1997025994A1 (en) | 1997-07-24 |
| IS4782A (is) | 1998-06-24 |
| HUP9902029A2 (hu) | 1999-11-29 |
| HUP9902029A3 (en) | 2001-01-29 |
| NZ326003A (en) | 2001-03-30 |
| ATE214280T1 (de) | 2002-03-15 |
| DE69711024D1 (de) | 2002-04-18 |
| EP0874634B1 (en) | 2002-03-13 |
| TR199801365T2 (xx) | 1998-10-21 |
| KR19990077331A (ko) | 1999-10-25 |
| JP2008163036A (ja) | 2008-07-17 |
| CZ225098A3 (cs) | 1998-10-14 |
| SE9600216D0 (sv) | 1996-01-18 |
| PL327828A1 (en) | 1999-01-04 |
| NO983295L (no) | 1998-07-16 |
| EP0874634A1 (en) | 1998-11-04 |
| IL125375A0 (en) | 1999-03-12 |
| JP2000503318A (ja) | 2000-03-21 |
| CA2241983A1 (en) | 1997-07-24 |
| AU701260B2 (en) | 1999-01-21 |
| CN1213309A (zh) | 1999-04-07 |
| NO983295D0 (no) | 1998-07-16 |
| BR9707005A (pt) | 1999-07-20 |
| US6174855B1 (en) | 2001-01-16 |
| AU1327197A (en) | 1997-08-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60100740T2 (de) | Verwendung von thrombin-derivierten peptiden zur therapie von kardiovaskuläre krankheiten | |
| DE69711024T2 (de) | Steuerung des heilungsprozesses | |
| DE69231421T2 (de) | Fibrin oder fibrinogen sowie biologisch abbaubare und biokompatible polymere enthaltende zusammensetzung zur gewebebehandlung | |
| DE69332624T2 (de) | WUNDHEILMITTEL UND BEHANDLUNG VON FIBROTISCHEN STORUNGEN DURCH TGFbeta-3 | |
| DE69425509T2 (de) | Lokale verabreichung von fibrinolyse verstärkendemitteln | |
| DE3856321T2 (de) | Sulfatierte Polysaccharide mit antiinflammatorischer Aktivität | |
| DE69327263T2 (de) | Verwendung des Gewebefaktor-Inhibitors zur Herstellung eines Arzneimittels gegen Mikrogefässthrombose | |
| US10034968B2 (en) | Multi-layered anti-adhesion device | |
| DE4200080A1 (de) | Pharmazeutische Zusammensetzung zur Wund-, Narben- und Keloidbehandlung | |
| US9421221B2 (en) | Compositions and methods for inhibiting adhesion formation | |
| DE69807710T2 (de) | Verwendung von Latenz Assoziierten Peptiden in der Herstellung eines Medikaments zur Verbesserung der Wundheilung. | |
| EP0430200A1 (de) | Arzneimittel zur subkutanen oder intramuskulären Applikation enthaltend Polypeptide | |
| DE69716460T2 (de) | Wundheilung und behandlung von fibrose | |
| DE3883645T2 (de) | Therapeutische Zusamensetzungen und Verfahren zur Verhinderung von Fibrinablagerung und Adhäsionen. | |
| EP0318801B1 (de) | Zubereitungsformen zur Verhinderung von Adhäsionen von Organen und Organteilen | |
| DE69107309T2 (de) | Verhütung der synovialischen adhäsion. | |
| DE69622863T2 (de) | Verwendung von hydroxyethylstärke zur verhinderung postoperativer adhäsion und als träger für innenhohlräume | |
| DE602004012894T2 (de) | Oberflächenschutz von frei liegenden biologischen geweben | |
| US9474767B2 (en) | Compositions and methods for inhibiting bone growth | |
| DD271268A5 (de) | Verfahren zur herstellung einer topisch anwendbaren pharmazeutischen zusammensetzung zur verhinderung von fibrinablagerungen oder verwachsungen | |
| EP1150702B1 (de) | Verwendung von orosomucoid zur herstellung einer pharmazeutischen präparation zur behandlung von pankreatitis | |
| DE69805316T2 (de) | Vorbeugung und behandlung von adhäsionbildung |